Iproclozide: Difference between revisions
Jump to navigation
Jump to search
Kiran Singh (talk | contribs) No edit summary |
m Protected "Iproclozide": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 43: | Line 43: | ||
| StdInChIKey = GGECDTUJZOXAAR-UHFFFAOYSA-N | | StdInChIKey = GGECDTUJZOXAAR-UHFFFAOYSA-N | ||
}} | }} | ||
__Notoc__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Iproclozide''' (trade names '''Sursum''', '''Sinderesin''') is an [[irreversible inhibition|irreversible]] and [[functional selectivity|selective]] [[monoamine oxidase inhibitor]] (MAOI) of the [[hydrazine]] [[chemical class]] that was used as an [[antidepressant]], but has since been [[discontinuation|discontinued]].<ref name="pmid5930723">{{cite journal | author = Suerinck A, Suerinck E. | title = [Depressive states in a sanatorium milieu and monoamine oxidase inhibitors. (Therapeutic results by the combination of iproclozide and chlordiazepoxide). Apropos of 146 cases] | journal = Journal de médecine de Lyon | volume = 47 | issue = 96 | pages = 573–586 | year = 1966 | pmid = 5930723 }}</ref> It has been known to cause [[Acute liver failure|fulminant hepatitis]] and there have been at least three reported fatalities due to administration of the drug.<ref name="pmid680506">{{cite journal | author = Pessayre D, de Saint-Louvent P, Degott C, Bernuau J, Rueff B, Benhamou JP. | title = Iproclozide fulminant hepatitis. Possible role of enzyme induction. | journal = Gastroenterology. | volume = 75 | issue = 3 | pages = 492–496 | year = 1978 | pmid = 680506 }}</ref><ref name="bookDrug-induced liver disease">{{cite book | author = Neil Kaplowitz, Laurie D. DeLeve | title = Drug-induced liver disease | publisher = Informa Health Care | year = 2003 | page = 455 | isbn = 0-8247-0811-3 |id=ISBN 9780824708115 }}</ref> | '''Iproclozide''' (trade names '''Sursum''', '''Sinderesin''') is an [[irreversible inhibition|irreversible]] and [[functional selectivity|selective]] [[monoamine oxidase inhibitor]] (MAOI) of the [[hydrazine]] [[chemical class]] that was used as an [[antidepressant]], but has since been [[discontinuation|discontinued]].<ref name="pmid5930723">{{cite journal | author = Suerinck A, Suerinck E. | title = [Depressive states in a sanatorium milieu and monoamine oxidase inhibitors. (Therapeutic results by the combination of iproclozide and chlordiazepoxide). Apropos of 146 cases] | journal = Journal de médecine de Lyon | volume = 47 | issue = 96 | pages = 573–586 | year = 1966 | pmid = 5930723 }}</ref> It has been known to cause [[Acute liver failure|fulminant hepatitis]] and there have been at least three reported fatalities due to administration of the drug.<ref name="pmid680506">{{cite journal | author = Pessayre D, de Saint-Louvent P, Degott C, Bernuau J, Rueff B, Benhamou JP. | title = Iproclozide fulminant hepatitis. Possible role of enzyme induction. | journal = Gastroenterology. | volume = 75 | issue = 3 | pages = 492–496 | year = 1978 | pmid = 680506 }}</ref><ref name="bookDrug-induced liver disease">{{cite book | author = Neil Kaplowitz, Laurie D. DeLeve | title = Drug-induced liver disease | publisher = Informa Health Care | year = 2003 | page = 455 | isbn = 0-8247-0811-3 |id=ISBN 9780824708115 }}</ref> | ||
== See also == | == See also == | ||
== References == | == References == | ||
| Line 54: | Line 56: | ||
{{Antidepressants}} | {{Antidepressants}} | ||
{{Anxiolytics}} | {{Anxiolytics}} | ||
[[Category:Monoamine oxidase inhibitors]] | [[Category:Monoamine oxidase inhibitors]] | ||
[[Category:Withdrawn drugs]] | [[Category:Withdrawn drugs]] | ||
[[Category:Phenol ethers]] | [[Category:Phenol ethers]] | ||
[[Category:Organochlorides]] | [[Category:Organochlorides]] | ||
[[Category:Drug]] | [[Category:Drug]] | ||
Latest revision as of 16:32, 20 August 2015
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C11H15ClN2O2 |
| Molar mass | 242.70 g/mol |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
|
WikiDoc Resources for Iproclozide |
|
Articles |
|---|
|
Most recent articles on Iproclozide Most cited articles on Iproclozide |
|
Media |
|
Powerpoint slides on Iproclozide |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Iproclozide at Clinical Trials.gov Clinical Trials on Iproclozide at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Iproclozide
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Iproclozide Discussion groups on Iproclozide Patient Handouts on Iproclozide Directions to Hospitals Treating Iproclozide Risk calculators and risk factors for Iproclozide
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Iproclozide |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Iproclozide (trade names Sursum, Sinderesin) is an irreversible and selective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant, but has since been discontinued.[1] It has been known to cause fulminant hepatitis and there have been at least three reported fatalities due to administration of the drug.[2][3]
See also
References
- ↑ Suerinck A, Suerinck E. (1966). "[Depressive states in a sanatorium milieu and monoamine oxidase inhibitors. (Therapeutic results by the combination of iproclozide and chlordiazepoxide). Apropos of 146 cases]". Journal de médecine de Lyon. 47 (96): 573–586. PMID 5930723.
- ↑ Pessayre D, de Saint-Louvent P, Degott C, Bernuau J, Rueff B, Benhamou JP. (1978). "Iproclozide fulminant hepatitis. Possible role of enzyme induction". Gastroenterology. 75 (3): 492–496. PMID 680506.
- ↑ Neil Kaplowitz, Laurie D. DeLeve (2003). Drug-induced liver disease. Informa Health Care. p. 455. ISBN 0-8247-0811-3. ISBN 9780824708115.
Categories:
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Drugboxes which contain changes to watched fields
- Monoamine oxidase inhibitors
- Withdrawn drugs
- Phenol ethers
- Organochlorides
- Drug